Home › NDC Lookup › Ingredients › Nystatin › 68382-0370-01
🧂image loading
(from DailyMed)

NYSTATIN 100000 [USP'U]/g Powder, 15 g — NDC 68382-370-01 (Billing 68382-0370-01)

by Zydus Pharmaceuticals USA Inc. · 15 g in 1 BOTTLE, PLASTIC

This is a package of 15 g of NYSTATIN 100000 [USP'U]/g Powder from Zydus Pharmaceuticals USA Inc., marketed since Oct 2021 and currently FDA-listed; retail pharmacies pay about $0.4214 per g (NADAC).

NDC 68382-0370-01
🏷️ FDA NDC (as labeled) 68382-370-01 billing pads the product segment with a zero
This package
Contains15 g Cost per g$0.4214 NADAC Per package$6.32 / 15 g Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.5677/unit · Part D plans $0.3744/unit — full pricing hub ↓
Product page 68382-0370-03 Also comes in: 30 g 68382-370-02 60 g 68382-370-03
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Nystatin (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jun 23, 2026 — Subpotent Drug: Low out of specification assay results performed during long-term stability testing. (Padagis US LLC) · FDA recall D-0677-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 68382-370-01
Product NDC 68382-370
11-digit billing NDC 68382037001
NCPDP billing unit GM — per gram (weight)
RxCUI 646456
UNII BDF1O1C72E
UPC 0368382370037, 0368382370013, 0368382370020
Application # ANDA208581
SPL Set ID 2daf159d-6a12-4b5d-97b3-8069c17e7635
Established class (EPC) Polyene Antifungal
Chemical class Polyenes
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-10-06
Route TOPICAL
Dosage form POWDER
Substance NYSTATIN
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90150080002920
GPI class Nystatin
GCN Seq No 007284
GCN 30160
HICL code 004129
Ingredient (HICL) Nystatin
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 08:14.28.00
AHFS class Polyene Antifungals
FDB label name NYSTATIN 100,000 UNIT/GM POWD
FDB brand name Nystatin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007284
  • GCN: 30160
  • GPI-14 (Medi-Span): 90150080002920
  • HICL (First Databank): 004129
  • AHFS class code: 08:14.28.00
  • RxCUI (RxNorm): 646456
Why two NDCs? The FDA registers this code as 68382-370-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 68382-0370-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Polyene Antifungal class.

Pharmacologic class Polyene Antifungal
Drug family (ATC) Antibiotics, Antibiotics, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name NYSTATIN 100,000 UNIT/GM POWD Ingredient Nystatin
📗 Our plain-language guide HelloPharmacist
  • It treats Candida yeast infections. Creams, ointment and powder are for the skin. The liquid is for the mouth. Tablets are for the digestive tract lining.
  • Place half the dose in each side of your mouth and keep it there as long as you can before swallowing. For babies, use the dropper and avoid feeding for 5 to 10 minutes. Keep going...
  • How do I use the liquid for a mouth infection?
  • Cream and ointment are usually applied twice a day. Powders are used two or three times a day. Keep using it until the area has healed, and follow your prescriber’s directions.
📖 Read our full Nystatin guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.421 $6.32 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.5677 $8.52 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.3744 $5.62 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Mar 2022 Oct 2022 Feb 2026 Sep 2026 $0.473 $0.306
▲ Up 20% over the last 22 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
68382-0370-01 You're viewing this 15 g in 1 BOTTLE, PLASTIC $0.4214 / g $6.32 2021-10-06 — Active
68382-0370-02 68382-370-02 30 g in 1 BOTTLE, PLASTIC $0.3134 / g $9.40 2021-10-06 — Active
68382-0370-03 68382-370-03 Main listing 60 g in 1 BOTTLE, PLASTIC $0.2574 / g $15.44 2021-10-06 — Active

You're viewing the smallest of 3 pack sizes for this product.

Per g, this pack runs about 64% above the cheapest pack (60 g, $0.2574 vs $0.4214 NADAC).

This pack accounts for about 30% of this product's recent Medicaid fills; the largest share goes to the 60 gs pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 15 g — 15 g in 1 bottle, plastic.
How does this package differ from NDC 68382-0370-02?
Both are NYSTATIN 100000 [USP'U]/g Powder — the drug itself is identical. This page's package is the 15 g one, while NDC 68382-0370-02 is the 30 g package. Per-g NADAC also differs: $0.4214 here vs $0.3134 for the 30 g pack.
What NDC number is used to bill for this package of NYSTATIN 100000 [USP'U]/g Powder?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Nystop 100000 [USP'U]/g 00574-2008-02 Padagis 60 g $0.257 AT Availability likely save 39%
Nystatin Topical Powder 100000 U/g 42806-0178-15 Epic 15 g $0.307 AT FDA listed save 27%
Nystatin 100000 [USP'U]/g 75907-0060-30 Dr. 30 g $0.313 AT Availability likely save 26%
Nyamyc 100000 [USP'U]/g 00832-0465-15 Upsher-Smith 1 bottle $0.421 AT Availability likely —
Klayesta 100000 U/g 42806-0186-15 Epic 15 g $0.421 AT Availability likely —
Nystatin 100000 [USP'U]/gthis 68382-0370-01 Zydus 15 g $0.421 AT Availability likely —
Nystatin 100000 [USP'U]/g 69315-0306-15 Leading 15 g $0.421 AT Availability likely —
Nystatin 100000 [USP'U]/g 72603-0491-01 Northstar 15 g $0.421 AT Availability likely —
Nystatin Topical Powder 100000 U/g 42806-0185-15 Epic 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 63629-8696-01 Bryant 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 63629-8697-01 Bryant 30 g — AT FDA listed —
Nystop 100000 [USP'U]/g 63629-8698-01 Bryant 60 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 70771-1585-01 Zydus 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 71335-2845-01 Bryant 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 71335-2869-01 Bryant 30 g — AT FDA listed —
Nystop 100000 [USP'U]/g 72162-1124-02 Bryant 15 g — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2021
On the market since
Oct 2021
📍
2026
Currently FDA-listed
5 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 7SEV7J4R1U
    A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.

1 inactive ingredient listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerZydus Pharmaceuticals USA Inc.
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA208581 (ANDA)
Labeler code68382
First marketedOct 2021
Product typeHuman Prescription Drug
Portfolio454 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 🧬 Pharmacokinetics 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 39 words ▾

INDICATIONS AND USAGE Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. Nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.

⏱️ Dosage and Administration 59 words ▾

DOSAGE AND ADMINISTRATION Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older) Apply to candidal lesions two or three times daily until healing is complete. For fungal infections of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.

⛔ Contraindications 18 words ▾

CONTRAINDICATIONS Nystatin topical powder is contraindicated in patients with a history of hypersensitivity to any of its components.

🤒 Adverse Reactions 41 words ▾

ADVERSE REACTIONS The frequency of adverse events reported in patients using nystatin topical powder is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS , General .)

🤰 Pregnancy 65 words ▾

Pregnancy Teratogenic Effects Category C Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical powder should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

🧒 Pediatric Use 22 words ▾

Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION .)

🧓 Geriatric Use 55 words ▾

Geriatric Use Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

🧬 Clinical Pharmacology 155 words ▾

CLINICAL PHARMACOLOGY Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane. Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Trichophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components.

On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well.

This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

📦 How Supplied / Storage and Handling 50 words ▾

HOW SUPPLIED Nystatin topical powder, USP is supplied as 100,000 units nystatin per gram in plastic squeeze bottles: 15 g (NDC 68382-370-01) 30 g (NDC 68382-370-02) 60 g (NDC 68382-370-03) STORAGE Store at 20°C to 25°C (68°F to 77°F)[see USP Controlled Room Temperature]; avoid excessive heat (40°C/104°F). Keep tightly closed.

📋 Description 34 words ▾

DESCRIPTION Nystatin is a polyene antifungal antibiotic obtained from Streptomyces noursei. Structural formula: Nystatin topical powder is for dermatologic use. Nystatin topical powder contains 100,000 USP nystatin units per gram dispersed in talc. Structure

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General Nystatin topical powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out other infection caused by other pathogens.

INFORMATION FOR THE PATIENT Patients using this medication should receive the following information and instructions: The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.

If symptoms or irritation develop, the patient should be advised to notify the physician promptly. Laboratory Tests If there is lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin.

No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility. Pregnancy Teratogenic Effects Category C Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity.

Nystatin topical powder should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus. Nursing Mother It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION .) Geriatric Use Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

🧬 Pharmacokinetics 11 words ▾

Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane.

📄 Package Label / Principal Display Panel 93 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 68382-370-01 Nystatin Topical Powder, USP FOR TOPICAL USE ONLY 100,000 units per gram Rx Only 15 GRAMS Zydus 15 g Bottle Label 15 g Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 68382-370-02 Nystatin Topical Powder, USP FOR TOPICAL USE ONLY 100,000 units per gram Rx Only 30 GRAMS Zydus 30 g Bottle Label 30 g Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 68382-370-03 Nystatin Topical Powder, USP FOR TOPICAL USE ONLY 100,000 units per gram Rx Only 60 GRAMS Zydus 60 g Bottle Label 60 g Bottle Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
47.7K
Units reimbursed last 4 qtrs
1M
Gross reimbursed last 4 qtrs
$578.9K
Avg / prescription
$12.14
Avg / unit
$0.5677
Latest quarter Q4 2025
10.9KRx
Medicaid pays / g
$0.5677
gross reimbursed
vs
NADAC / g
$0.4214
acquisition cost
=
Spread
+$0.1463
+35% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
34% FFS 66% MCO
Fee-for-service · 16,066 Rx Managed care · 31,615 Rx
State Medicaid map
Alaska: 810 units · 111 per 100k residents AK Maine: 2,415 units · 173 per 100k residents ME Washington: 19,861 units · 254 per 100k residents WA Idaho: 2,385 units · 121 per 100k residents ID Montana: 1,245 units · 110 per 100k residents MT North Dakota: no data reported ND Minnesota: 23,265 units · 406 per 100k residents MN Wisconsin: 7,260 units · 123 per 100k residents WI Michigan: 19,695 units · 196 per 100k residents MI New York: 38,491 units · 197 per 100k residents NY Vermont: 1,289 units · 199 per 100k residents VT New Hampshire: 3,315 units · 236 per 100k residents NH Oregon: 9,090 units · 215 per 100k residents OR Nevada: 16,761 units · 525 per 100k residents NV Wyoming: 375 units · 64.2 per 100k residents WY South Dakota: no data reported SD Iowa: 4,170 units · 130 per 100k residents IA Illinois: 16,185 units · 129 per 100k residents IL Indiana: 23,865 units · 348 per 100k residents IN Ohio: 59,265 units · 503 per 100k residents OH Pennsylvania: 19,185 units · 148 per 100k residents PA New Jersey: 27,870 units · 300 per 100k residents NJ Massachusetts: 64,621 units · 923 per 100k residents MA California: 86,727 units · 223 per 100k residents CA Utah: 3,105 units · 90.9 per 100k residents UT Colorado: 12,525 units · 213 per 100k residents CO Nebraska: 6,300 units · 319 per 100k residents NE Missouri: 24,285 units · 392 per 100k residents MO Kentucky: 28,084 units · 621 per 100k residents KY West Virginia: 5,655 units · 319 per 100k residents WV Virginia: 56,782 units · 651 per 100k residents VA Maryland: 18,928 units · 306 per 100k residents MD Connecticut: 40,545 units · 1,121 per 100k residents CT Rhode Island: 17,296 units · 1,580 per 100k residents RI Arizona: 27,989 units · 377 per 100k residents AZ New Mexico: 6,405 units · 303 per 100k residents NM Kansas: 7,560 units · 257 per 100k residents KS Arkansas: 14,761 units · 481 per 100k residents AR Tennessee: 15,405 units · 216 per 100k residents TN North Carolina: 46,803 units · 432 per 100k residents NC South Carolina: 25,851 units · 481 per 100k residents SC Delaware: no data reported DE Oklahoma: 11,520 units · 284 per 100k residents OK Louisiana: 23,813 units · 521 per 100k residents LA Mississippi: 7,236 units · 246 per 100k residents MS Alabama: 13,242 units · 259 per 100k residents AL Georgia: 41,716 units · 378 per 100k residents GA D.C.: 2,686 units · 396 per 100k residents DC Hawaii: 4,425 units · 308 per 100k residents HI Texas: 45,067 units · 148 per 100k residents TX Florida: 63,505 units · 281 per 100k residents FL
Units reimbursed · per 100k residents
64.21,580
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Rhode Island 1,580 /100k
2 Connecticut 1,121 /100k
3 Massachusetts 923 /100k
4 Virginia 651 /100k
5 Kentucky 621 /100k
6 Nevada 525 /100k
7 Louisiana 521 /100k
8 Ohio 503 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
60 gs68382-0370-03 75,624 Rx · $1,746,146
15 gs this page68382-0370-01 47,681 Rx · $578,893
30 gs68382-0370-02 34,174 Rx · $590,576
Drug total (last 4 qtrs): 157,479 Rx · 7,175,940 units · $2,915,615 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Nystatin — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Nystatin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$16.29M
Claims incl. refills
853.7K
Beneficiaries
614.3K
Spend / beneficiary
$26.52
Spend / claim
$19.08
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 68382-0358-01 · Zydus 68382-0383-06 · Zydus →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.